Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd is positioned for positive growth due to its strategic initiatives, including an expanded agreement with STEMCELL Technologies aimed at strengthening rhCollagen supply, which is critical for both its regenerative and aesthetic medicine offerings. The company differentiates itself in the market with its proprietary Collink.3D technology, which has shown superior performance in structured tissue formation compared to leading animal-derived matrices, paving the way for potential first-to-market advantages in the attractive breast implant sector. Furthermore, the establishment of a U.S.-based logistics center is expected to boost sales of its BioInk and rhCollagen products, complemented by a new distribution agreement in Poland that aims to expand the reach of its Vergenix STR product across Europe, thereby enhancing overall market presence and revenue potential.

Bears say

CollPlant Biotechnologies has faced challenges in generating sustainable revenue streams from its business collaborations and product sales, particularly in the competitive fields of regenerative medicine and aesthetics. Despite its innovative rhCollagen technology, the company continues to encounter market penetration difficulties and a reliance on a limited portfolio of products, which may hinder its growth potential. Additionally, the financial performance in key regions such as the United States and Europe has shown signs of volatility, raising concerns about the company’s ability to achieve consistent profitability moving forward.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.